玉溪沃森生物技术有限公司
2023-02-28
玉溪沃森生物技术有限公司(以下简称“玉溪沃森”)成立于2005年,为云南沃森生物技术股份有限公司控股子公司,位于云南省玉溪市高新技术产业开发区,占地面积128亩。已分三期建成现代化疫苗生产厂房面积11万平方米,投入建设资金累计约13亿元,其中一期总建筑面积约15000m2(租赁玉溪泽润和玉溪嘉和),二期总建筑面积21720m2,包括百白破原液车间、分包装中心等建筑,三期总建筑面积63610 m2,包括流脑疫苗原液、Hib结合疫苗原液、肺炎疫苗原液车间等。是目前国内符合欧盟标准的现代化生物制药厂,配备大量国际先进的疫苗生产和检测设备,设计年产能可达17000万剂,已有6条生产线通过GMP认证并投入生产。公司现有员工640人,其中高级职称3人,中级职称15人,生产和质量人员占员工总数的89% ,人员的配备符合GMP对药品生产企业的要求。公司力争打造成世界级高端疫苗生产基地,成为国际疫苗组织采购大型供应商。
Search
Latest News
-
2024-02-02
The medical expert team from the Shaanxi Provincial Medical Exchange Promotion Association (SXIMEA) embarked on an exchange visit to Tajikistan.
-
2024-01-31
A delegation from Samarkand Region, Uzbekistan, visited the Weinan Haicheng Dermatology Hospital, a Vice-Chairman Unit of the Shaanxi International Medical Exchange Promotion Association (SXIMEA), and signed a cooperation agreement.
-
2024-01-19
Shaanxi medical experts went to Tajikistan for exchanges and conducted free medical consultations.
-
2024-01-10
Professor Jiao, Fuyong, Vice Chairman of the Shaanxi International Medical Exchange Promotion Association (SXIMEA), participated in the launch of the Chinese Kawasaki Disease Diagnosis and Treatment Guidelines for Children.